Feb 19, 2021
Dr. Douglas Harrington has over 25 years of
experience in the research, development,
commercialization, and expansion of innovative healthcare technology and services. Dr.
Harringtonwas a member of one of the first
heart transplant teams led by Dr. Jack
Copeland from Stanford University. He-founded one of the first clinical molecular biology
laboratories in the U.S. with the
Nebraska Lymphoma StudyGroup headed by Dr.
Jim Armitage. As President and LabDirector
of Nichols Institute, Dr. Harrington expanded their
molecular genetics, infectious disease,
immunology, cytogenetic, and anatomic
pathology offerings. Dr. Harringtonled the
team that developed one of the first digital microscopes
targeted at minimal residual disease and
circulating tumor cells as the founder
and CEO of Clarient. Dr.Harrington also led
the turnaround and reinstatement of the federal license of Specialty Laboratories, a New York
StockExchange company, as CEO and
Dr. Harrington has developed patents for an automated method for image analysis of residual cancer cells, a patent covering catalytic heavy metal extraction, and a patent-pending on biomarker assay for diagnosis and classification of cardiac disease. He has been involved as a director or founder of multiple startup companies - from devices to molecular genetics focusing on immunology, cancer, and cardiology, where he has taken several new molecular technologies through state and federal regulatory approval and has been involved in the commercialization of over 200 academic discoveries. He is a member of Phi Beta Kappa, the nation's most prestigious academic honor society.
Dr. Harrington is the inventor of the PULS Cardiac Test (TM), a breakthrough blood test for the detection of the leading cause of heart attacks, and CEO & Laboratory Director of global Discovery Biosciences. Throughout his career, Dr.Harrington has remained a Clinical Professor of Pathology at the USC Keck School of medicine, a published author of numerous peer-reviewed papers, and a sought-after speaker in the area of preventive medicine and technology development. Dr. Harrington received his BA in molecular biology, his MD from the University of Colorado HealthSciences Center, and is board-certified in hematology, anatomic and clinical pathology.